Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | PTPRF | P10586 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965213 | 0.92 | MTNR1A (0.38) | PTPN1PTPN2PTPN6MTNR1AMTNR1B | |
| SCHEMBL965212 | 0.92 | MTNR1A (0.38) | PTPN1PTPN2PTPN6MTNR1AMTNR1B | |
| SCHEMBL965202 | 0.83 | ADRB2 (0.41) | PTPN1PTPN2PTPN6MTNR1AMTNR1B | |
| SCHEMBL965203 | 0.83 | ADRB2 (0.41) | PTPN1PTPN2PTPN6MTNR1AMTNR1B | |
| SCHEMBL2054498 | 0.78 | MTNR1A (0.42) | MTNR1AMTNR1BL3MBTL1ALDH1A1 | |
| SCHEMBL2100994 | 0.77 | ADRB2 (0.42) | MTNR1AMTNR1B | |
| SCHEMBL2100995 | 0.77 | ADRB2 (0.42) | MTNR1AMTNR1B | |
| SCHEMBL2054497 | 0.77 | ADRB2 (0.42) | MTNR1AMTNR1B | |
| SCHEMBL963818 | 0.76 | ADRB2 (0.43) | PTPN1PTPN2PTPN6MTNR1AMTNR1B | |
| SCHEMBL965218 | 0.76 | CASP1 (0.37) | MTNR1AMTNR1BBACE1ALDH1A1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | PTPN1 1867/4885PTPN2 1478/4885PTPN6 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.